1114 - Exploring bactericidal activity and emergence of resistance for carbapenem-resistant Enterobacterales (CRE) with and without Klebsiella pneumoniae carbapenemase (KPC) treated with optimized meropenem (MEM) and meropenem-vaborbactam (MEV) exposures

Friday, October 13, 2023

11:30 AM – 11:43 AM US ET

Location: 102 AB

Co-Author(s)

KS

Kevin M. Squires, M.Ed., B.S.

University of Pittsburgh
Pittsburgh, Pennsylvania, United States
EK

Ellen G. Kline, MS

University of Pittsburgh
Pittsburgh, Pennsylvania, United States
CJ

Chelsea Jones, BS

UPMC
Pittsburgh, Pennsylvania, United States

Presenting Author(s)

Ryan K. Shields, PharmD, MS

Associate Professor of Medicine
University of Pittsburgh
Pittsburgh, PA, United States

Slides

Disclosure(s):

Ryan K. Shields, PharmD, MS: Allergan: Advisor/Consultant (); Cidara: Advisor/Consultant (); Entasis: Advisor/Consultant (); GSK: Advisor/Consultant (); Melinta: Advisor/Consultant (), Grant/Research Support (); Menarini: Advisor/Consultant (); Merck: Advisor/Consultant (), Grant/Research Support (); Pfizer: Advisor/Consultant (); Roche: Grant/Research Support (); Shionogi: Advisor/Consultant (), Grant/Research Support (); Utility: Advisor/Consultant (); Venatorx: Advisor/Consultant (), Grant/Research Support ()